Bristol-Myers Squibb BMY Free cash flow margin
Free cash flow margin at other companies
Other financials
Where this comes from
Calculated from Bristol-Myers Squibb’s reported figures.
Based on trailing twelve months.
The official record: Bristol-Myers Squibb’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bristol-Myers Squibb's free cash flow margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bristol-Myers Squibb's free cash flow margin?
- Bristol-Myers Squibb (BMY) reported free cash flow margin of 24.6% in Q1 2026.
- How has Bristol-Myers Squibb's free cash flow margin changed year-over-year?
- Bristol-Myers Squibb's free cash flow margin decreased by 10.6% year-over-year, from 27.5% to 24.6%.
- What is the long-term trend for Bristol-Myers Squibb's free cash flow margin?
- Over 4 years (2021 to 2025), Bristol-Myers Squibb's free cash flow margin has grown at a -1.1% compound annual growth rate (CAGR), from 122% to 116.5%.
- What does free cash flow margin mean?
- How much real, spendable cash each sales dollar generates after reinvestment.
- How do you interpret free cash flow margin?
- A high and rising FCF margin is the hallmark of a cash-generative business. Persistent gaps between net margin and FCF margin warrant a look at working capital or capital intensity.
- How does free cash flow margin compare across companies?
- Strong cross-company quality signal; capital-light compounders post structurally higher FCF margins than asset-heavy peers.